Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
HBIO 
Harvard Bioscience Inc (HBIO)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/11/2025: HBIO (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $2
1 Year Target Price $2
| 1 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 36.39% | Avg. Invested days 38 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 09/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 19.66M USD | Price to earnings Ratio - | 1Y Target Price 2 |
Price to earnings Ratio - | 1Y Target Price 2 | ||
Volume (30-day avg) 2 | Beta 1.55 | 52 Weeks Range 0.28 - 3.04 | Updated Date 09/12/2025 |
52 Weeks Range 0.28 - 3.04 | Updated Date 09/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.29 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -64.68% | Operating Margin (TTM) -3.03% |
Management Effectiveness
Return on Assets (TTM) -1.98% | Return on Equity (TTM) -138.36% |
Valuation
Trailing PE - | Forward PE 14.93 | Enterprise Value 55621586 | Price to Sales(TTM) 0.22 |
Enterprise Value 55621586 | Price to Sales(TTM) 0.22 | ||
Enterprise Value to Revenue 0.63 | Enterprise Value to EBITDA 179.26 | Shares Outstanding 44531200 | Shares Floating 33721250 |
Shares Outstanding 44531200 | Shares Floating 33721250 | ||
Percent Insiders 10.07 | Percent Institutions 54.76 |
Upturn AI SWOT
Harvard Bioscience Inc
Company Overview
History and Background
Harvard Bioscience, Inc. was founded in 1901. Initially focused on teaching materials, it evolved into a global developer, manufacturer, and seller of scientific instruments, specializing in life science research.
Core Business Areas
- Cellular and Molecular Research: Offers a range of instruments and consumables for cell culture, electrophysiology, and molecular biology research.
- Preclinical Research: Provides equipment and services for in vivo physiology, pharmacology, and toxicology studies.
- Clinical Research: Offers products for clinical research applications and clinical diagnostics.
Leadership and Structure
The leadership team consists of experienced executives in the life science and medical device industries. The company operates with a global organizational structure, with manufacturing and sales operations worldwide.
Top Products and Market Share
Key Offerings
- Data Acquisition Systems: These systems collect and analyze data from physiological experiments. Market share data unavailable. Competitors include ADInstruments and DSI (Data Sciences International).
- Syringe Pumps: Used for precise fluid delivery in research and clinical settings. Market share data unavailable. Competitors include KD Scientific and World Precision Instruments.
- Ventilators: Small animal ventilators. Market share data unavailable. Competitors include Kent Scientific and RWD Life Science.
Market Dynamics
Industry Overview
The life science research tools market is driven by increasing R&D spending, advancements in technology, and the growing demand for personalized medicine.
Positioning
Harvard Bioscience holds a niche position focusing on specialized instruments and consumables for academic and pharmaceutical research labs. Their competitive advantage lies in their legacy brand and specialized product offerings.
Total Addressable Market (TAM)
The global life science tools market is projected to reach hundreds of billions of USD. Harvard Bioscience Inc. is positioned to address a portion of this TAM with its specific product lines.
Upturn SWOT Analysis
Strengths
- Strong brand reputation
- Specialized product portfolio
- Established customer base
- Global sales and distribution network
Weaknesses
- Limited scale compared to larger competitors
- Dependence on research funding
- Inconsistent profitability
- High debt level
Opportunities
- Expanding into emerging markets
- Developing new innovative products
- Acquiring complementary businesses
- Leveraging digital marketing and e-commerce
Threats
- Increased competition
- Economic downturn impacting research funding
- Technological disruptions
- Regulatory changes in the life science industry
Competitors and Market Share
Key Competitors
- ADInstruments
- Thermo Fisher Scientific (TMO)
- Danaher Corporation (DHR)
- Charles River Laboratories (CRL)
Competitive Landscape
Harvard Bioscience competes with larger, more diversified companies with greater resources. Its competitive advantage lies in its specialized products and established customer relationships, but it must continuously innovate to maintain its position.
Major Acquisitions
Data Sciences International (DSI)
- Year: 2018
- Acquisition Price (USD millions): 85
- Strategic Rationale: Expanded Harvard Bioscience's in vivo physiology product offerings.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been inconsistent, with periods of revenue growth followed by periods of decline. The company has struggled to achieve consistent profitability.
Future Projections: Future growth projections are dependent on successful execution of strategic initiatives and favorable market conditions. Analyst estimates suggest moderate revenue growth.
Recent Initiatives: Recent initiatives include new product launches, cost reduction programs, and strategic acquisitions.
Summary
Harvard Bioscience is a niche player in the life science research tools market, leveraging a strong brand and specialized product portfolio. Its inconsistent profitability and high debt levels are concerns. Key areas for improvement are sustainable growth and innovation in a very competitive market where the larger players dominate.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
Disclaimers:
This analysis is based on publicly available information and is for informational purposes only. It is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Harvard Bioscience Inc
Exchange NASDAQ | Headquaters Holliston, MA, United States | ||
IPO Launch date 2000-12-07 | President, CEO & Director Mr. John Duke | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 330 | |
Full time employees 330 | |||
Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States, Germany, and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.